Go to menu Skip to content
Dr. Klaudia Brodaczewska's team

About Us

Our team conducts basic oncology research, focusing on identifying and analyzing the molecular mechanisms responsible for cancer initiation, progression, and resistance to therapy. We conduct extensive preclinical studies, testing various therapeutic strategies using an extensive panel of cell lines and diverse culture conditions, allowing for a comprehensive assessment of the efficacy and safety of new therapeutic approaches.

 

In parallel, we are developing advanced in vitro models that enable in-depth analyses of pathomechanisms not only in oncology, but also in other inflammatory, metabolic and degenerative diseases.

 

The team collaborates intensively with clinicians, combining basic research with clinical practice. We characterize the immune response in various disease entities and analyze the expression of microRNAs (miRNAs) as potential biomarkers and regulators of pathophysiological processes. Our research covers diseases such as nephrology, cardiology, neurology, and dermatology.

 

We actively participate in clinical trials and medical experiments, managing the exploratory portion of these projects. Our activities include research on the mechanisms of the so-called "COVID fog," advanced therapies for throat cancer, and gastrointestinal and vascular diseases. Through the synergy of laboratory and clinical research, we contribute to the development of translational medicine and the implementation of innovative diagnostic and therapeutic solutions.

 

 

The team consists of:

 
PhD students/Fellows

 

About

Our research team conducts basic studies in oncology, focusing on the molecular mechanisms underlying tumor initiation, progression, and therapeutic resistance. We perform comprehensive preclinical investigations that include testing various anticancer therapeutic strategies using an extensive panel of cell lines under diverse culture conditions. This approach enables robust evaluation of treatment efficacy and safety, as well as the identification of novel therapeutic targets.

 

In parallel, we develop advanced in vitro models that allow in-depth exploration of disease mechanisms not only in oncology but also in other pathological conditions with inflammatory, metabolic, or degenerative backgrounds.

 

We maintain close collaboration with patients, integrating basic science with clinical practice. Together, we characterize immune responses in various diseases and investigate microRNA (miRNA) expression profiles as potential biomarkers and regulators of pathophysiological processes. Our research encompasses nephrological, cardiological, neurological, and dermatological disorders.

 

The team actively participates in clinical trials and medical experiments, contributing to the exploratory and analytical components of translational projects. Our work includes studies on post-COVID cognitive dysfunction (“brain fog”), throat cancers, and gastrointestinal and vascular diseases. By bridging laboratory research with clinical application, we contribute to the advancement of translational medicine and the development of innovative diagnostic and therapeutic strategies.

 

 

The group consists of:

 
PhD Students/scholarships